AKT1 and malignant peripheral nerve sheath tumor: At 4 h and 2 days of treatment, ERK1/2, S6 (S240/S244 and S235/S236), and p90RSK demonstrated the strongest decrease in phosphorylation in all of the MPNST models, suggesting that the RAS/ERK and AKT/mTOR pathways are robustly inactivated with combined MET-MEK inhibition (Figure 3D–F).